

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **HUAKANG BIOMEDICAL HOLDINGS COMPANY LIMITED**

**華康生物醫學控股有限公司**

*(Incorporated in Cayman Islands with limited liability)*

**(Stock Code: 8622)**

### **INSIDE INFORMATION TRANSFER OF SHARES BY SUBSTANTIAL SHAREHOLDER**

This announcement is made by the board (the "**Board**") of directors (the "**Directors**") of Huakang Biomedical Holdings Company Limited (the "**Company**") pursuant to Rule 17.10 of the Rules Governing the Listing of Securities on GEM of The Stock Exchange of Hong Kong Limited (the "**GEM Listing Rules**") and the Inside Information Provisions (as defined under the GEM Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong).

The Company was informed by Mr. Zhang Shuguang ("**Mr. Zhang**"), an executive Director, the chairman of the Board and a substantial shareholder (as defined under the GEM Listing Rules) of the Company that he has sold the entire issued share capital in Crystal Grant Limited (a substantial shareholder of the Company, which in turns held 138,672,000 ordinary shares in the Company, representing approximately 27.71% of the total issued shares of the Company as at the date of this announcement) ("**Crystal Grant**") to an independent third party purchaser (the "**Purchaser**") on 10 January 2025 (the "**Transfer**").

Immediately after the Transfer, Mr. Zhang ceased to be a substantial shareholder of the Company. The Purchaser holds (via Crystal Grant) 138,672,000 ordinary shares of the Company, representing approximately 27.71% of the issued share capital of the Company as at the date of this announcement, will become a substantial shareholder of the Company (as defined under the GEM Listing Rules).

**Shareholders of the Company and potential investors should exercise caution when dealing in the securities of the Company.**

By Order of the Board  
**Huakang Biomedical Holdings Company Limited**  
**Zhang Shuguang**  
Chairman and Executive Director

Hong Kong, 14 January 2025

*As at the date of this announcement, the executive Directors are Mr. Zhang Shuguang, Mr. Zhang Chunguang, Mr. Poon Lai Yin Michael and Mr. He Jiaming; the Non-executive Directors are Dr. Bu Su and Dr. Xu Ming; and the independent non-executive Directors are Dr. Chow Kwok Fai Joseph, Dr. Cheng Faat Ting Gary, Ms. Chow Ching Man and Ms. Shih Mei Ling.*

*This announcement, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the Rules Governing the Listing of Securities on GEM of The Stock Exchange of Hong Kong Limited for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that, to the best of their knowledge and belief, the information contained in this announcement is accurate and complete in all material respects and not misleading or deceptive, and there are no other matters the omission of which would make any statement herein or this announcement misleading.*

*This announcement will remain on the “Latest Company Announcements” page of the Stock Exchange website at [www.hkexnews.hk](http://www.hkexnews.hk) for at least seven days from the date of publication and on the Company’s website at [www.huakangbiomedical.com](http://www.huakangbiomedical.com).*